VivoSim Labs, INC.
VIVS evidence brief
What we can confirm
- BioSniper Score:
- 2.6 / 10
- Market Cap:
- $3.8M
- Cash Runway:
- 1.6 mo
What it means
What to watch
Prepared research question
What matters most for VIVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VIVS
VivoSim Labs, Inc. (VIVS) is a biotechnology company that shifted from clinical-stage drug development (FXR314 for IBD) to a service model centered on proprietary 3D human tissue models (NAMkind™) for preclinical safety testing, with a cash position of $1.7M as of June 30, 2026 and an accumulated deficit of $357.3M.
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for VivoSim Labs, INC..
VivoSim Labs, Inc. (VIVS) is a biotechnology company that shifted from clinical-stage drug development (FXR314 for IBD) to a service model centered on proprietary 3D human tissue models (NAMkind™) for preclinical safety testing, with a cash position of $1.7M as of June 30, 2026 and an accumulated deficit of $357.3M.
- Cash and cash equivalents of $1.7M as of June 30, 2026, with an accumulated deficit of $357.3M [sec_mda · as of 2026-08-12].
- Total revenue of $0.0M and net income of -$1.3M for the latest reported period as of June 30, 2026 [sec].
- Shareholders' equity of -$2.3M as of June 30, 2026 [sec].
- Company pivoted from clinical-stage development of FXR314 in IBD to a service model using NAMkind™ 3D human tissue models for preclinical safety testing [sec · filed 2026-07-31].
- Presented new drug toxicity data at EUROTOX 2026 demonstrating predictive superiority in liver and gastrointestinal safety [news · published 2026-09-16].
What works
- Proprietary NAMkind™ platform achieved 87.5% sensitivity and 100% specificity in liver toxicity prediction, which the company describes as 'world's best' [sec · filed 2026-07-31].
- Company has demonstrated ability to discern antibody toxicity from payload toxicity in ADCs, opening a major new market [news · published 2026-03-24].
- FDA announcement on April 10, 2025 to refine animal testing requirements in favor of non-animal NAM methods may accelerate adoption of the company's models [sec · filed 2026-07-31].
What to weigh
- Company has zero revenue ($0.0M) and a net loss of -$1.3M as of June 30, 2026 [sec].
- Accumulated deficit of $357.3M as of June 30, 2026, indicating significant historical losses [sec_mda · as of 2026-08-12].
- Shareholders' equity is negative at -$2.3M as of June 30, 2026 [sec].
- Cash and cash equivalents of only $1.7M as of June 30, 2026, with restricted cash of $0.1M, suggesting limited runway [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Cash position and accumulated deficit
“As of June 30, 2026, we had cash and cash equivalents of approximately $1.7 million, restricted cash of approximately $0.1 million and an accumulated deficit of $357.3 million.”
SEC MD&A · August 12, 2026
Platform performance metrics
“we believe at 87.5% is a world's best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform.”
SEC filings · July 31, 2026
Pivot from drug development to service model
“Prior to March 2025, we were a clinical stage biotechnology company that was focused on developing FXR314 in inflammatory bowel disease ("IBD"), including ulcerative colitis ("UC"), based on demonstration of clinical promise in 3D human tissues as well as strong preclinical data.”
SEC filings · July 31, 2026
FDA regulatory tailwind for NAM methods
“We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods.”
SEC filings · July 31, 2026
Risks & what to watch (4)›
Key risks
- Cash runway — Only $1.7M cash as of June 30, 2026, with zero revenue, raising concerns about near-term liquidity [sec_mda · as of 2026-08-12].
- Negative equity — Shareholders' equity of -$2.3M as of June 30, 2026 indicates liabilities exceed assets [sec].
- Revenue generation — No revenue reported ($0.0M) as of June 30, 2026, meaning the service model has not yet generated sales [sec].
- Accumulated deficit — Accumulated deficit of $357.3M as of June 30, 2026 reflects sustained historical losses [sec_mda · as of 2026-08-12].
What to watch
- Adoption of NAMkind™ platform by pharmaceutical companies following FDA's April 2025 guidance on non-animal methods [sec · filed 2026-07-31].
- Ability to convert pipeline of bespoke service contracts into revenue, given zero revenue as of June 30, 2026 [sec].
- Progress of FXR314 pipeline candidate, which remains listed as Phase 2 for IBD and MASH [pipeline].
- Cash burn rate and any new financing or partnership announcements given limited cash runway [sec_mda · as of 2026-08-12].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run VivoSim Labs, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available VivoSim Labs, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.6 months
OCF -$3M · Net income -$1M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$140K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 36,850 | $53K |
| goldman sachs group inc | 16,072 | $23K |
| vanguard capital management llc | 15,371 | $22K |
| blackrock, inc. | 11,817 | $17K |
| vanguard fiduciary trust co | 7,003 | $10K |
| citigroup inc | 6,504 | $9K |
| tower research capital llc (trc) | 2,308 | $3K |
| ubs group ag | 952 | $1K |
| sbi securities co., ltd. | 221 | $316 |
| allworth financial lp | 208 | $298 |
Showing top 10 of 24 institutional holders of VivoSim Labs, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 1.8%
- Days to cover
- 0.8
- Shares short
- 52,788
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VIVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for VivoSim Labs, INC.?
VivoSim Labs, Inc. (VIVS) is a biotechnology company that shifted from clinical-stage drug development (FXR314 for IBD) to a service model centered on proprietary 3D human tissue models (NAMkind™) for preclinical safety testing, with a cash position of $1.7M as of June 30, 2026 and an accumulated deficit of $357.3M.
What is VivoSim Labs, INC.'s lead drug candidate?
VivoSim Labs, INC.'s most advanced tracked candidate is fxr314 (Phase 2) for Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD); metabolic function-associated steatohepatitis (MASH).
Who is the CEO of VivoSim Labs, INC.?
Douglas Jay Cohen is the chief executive officer of VivoSim Labs, INC. (VIVS).
Where is VivoSim Labs, INC. headquartered?
VivoSim Labs, INC. (VIVS) is headquartered in San Diego, CA, United States.
What therapeutic areas does VivoSim Labs, INC. focus on?
VivoSim Labs, INC. develops therapies across Immunology, Infectious Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.